Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR) and Corvus Pharmaceuticals Inc (CRVS)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nektar Therapeutics (NKTR) and Corvus Pharmaceuticals Inc (CRVS) with bullish sentiments.

Nektar Therapeutics (NKTR)

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Nektar Therapeutics, with a price target of $86. The company’s shares closed on Friday at $34.02, close to its 52-week low of $33.50.

According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 1.3% and a 36.9% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Pieris Pharmaceuticals.

Nektar Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $71.75, which is an 110.9% upside from current levels. In a report issued on November 8, Mizuho Securities also reiterated a Buy rating on the stock with a $103 price target.

.

See today’s analyst top recommended stocks >>

Corvus Pharmaceuticals Inc (CRVS)

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Corvus Pharmaceuticals Inc yesterday. The company’s shares closed on Friday at $7.91, close to its 52-week low of $6.81.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 7.0% and a 42.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Corvus Pharmaceuticals Inc with a $15 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts